🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What kind of childhood makes a top scientist? Is it enough to have all the right traits (brilliance, grit, etc) or do you need the right family too? And why should we care? A 🧵 on our paper on the Nobel Laureates. A teaser: the income distribution of the laureates' fathers.1/N

1/18: Well, after 23 years as faculty at Harvard and almost 15 years of amazing collaborations, collegiality and growth at McLean Hospital, today I officially start at UC Irvine, where I will be the founding director of a new depression

A great way to spend your friday: drinks and (science about) psychedelics

An awesome opportunity to work with an awesome scientist and person in an awesome place

Come join us at what I think is one of the coolest places to work, study, and thrive, all while expanding our understanding of psychedelics 🪐

CPCR postdoc Rebecca Ehrenkranz (Rebecca Ehrenkranz, PhD, MPH) will be presenting a poster at the Perspectives on Scientific Error workshop in Bern! Her presentation will focus on strategies to increase independence in research and reduce bias in psychedelic studies. errorsin.science

Beware the ‘know-cebo’ effect in psychedelic trials. Another reason to care about more careful comparators to the high-dose psychedelic condition. Larger between-condition effects could in part be artifacts of poor blinding and resulting know-cebo or disappointment effects.

Here at Hopkins, we now have a clinic for people experiencing difficulties after a psychedelic experience--the first of it's kind. Please share widely to help get the word out for those who might need help!

Looking forward to presenting some exciting work on the impacts of guides/facilitators/therapists on people's psychedelic subjective effects, using data spanning several clinical trials.

We want to hear your opinions about clinical trial research! What are the reasons you might not be able to join a clinical trial? We are conducting a survey study to understand concerns and challenges related to clinical trial participation, including factors influencing

‼️Compelling new RCT work on psilocybin for AUD led by the outstanding Nathalie M. Rieser! Raises important questions about what might and might not work in psychedelic-assisted treatment for AUD. A monumental effort that grows our knowledge of psychedelics👏

How awe-inspiring are psychedelic experiences and why might emotions like awe play a role in psychedelics' benefits? Excited to speak on this in our Society for Affective Science symposium on awe today! #AffectScience2025 #SAS2025

New in Research Ethics: "Enhanced independence: De-biasing processes in psychedelic research and beyond" RCTs aren't immune to bias—and perceived bias in psychedelic trials is an issue. Katherine Cheung Rebecca Ehrenkranz, PhD, MPH @existwell propose 4 independence-enhancing practices: -

‼️Excited to speak at this year's Breaking Convention! I'll cover our work on how much people's subjective effects differ by who guides them, spanning years of clinical trials and hundreds of participants at Johns Hopkins Psychedelic Research Center. First time attending #breakingconvention 👋

Huge thanks to Centre for Psychedelic Research (s/o Dr Rayyan Zafar!) and Psychology at Edinburgh (s/o Alex N. Fisher!) for hosting me and sparking some great discussions on psychedelics, well-being, and more. (I promise I have more than one outfit)